Monday, October 30, 2006

Point Therapeutics Reports Positive Results

Point Therapeutics Inc. (POTP) reported positive results for talabostat in an osteosarcoma model. Shares of the biopharmaceutical gained 24 cents to close at $1.49.

0 Comments:

Post a Comment

<< Home